Hey there, readers! Take a look at our GPCR coverage for this week. We've got 11 GPCR papers, seven industry news pieces, a new GPCR event, and even a job ad.   This week's highlight includes congrats to: Miles Thompson , Alexander Hauser , Caroline Gorvin ,   et al.   for their work on GPCR gene variants and human genetic disease Ilana Kotliar , Thomas Sakmar , et al. for their study on Multiplexed mapping of the interactome of GPCRs with receptor activity-modifying proteins Nicholas Kapolka , Geoffrey Taghon , and Daniel Isom  for their research on Advances in yeast synthetic biology for human GPCR biology and pharmacology Dr. GPCR University Early-Bird Registration Open for Premium Members! Unlock a 25% exclusive discount on these courses with Dr. Terry Kenakin with our premium membership and enjoy a 1-month FREE trial! Don’t miss out—secure your spot today! Registrations for the public will be on Monday! Hurry! Courses Schedule and  Benefits Every Thursday at 10 am EST Online Lectures 1:1 meeting with Dr. Terry Kenakin Reading Materials Access to the private group Certificate of participation Learn the essentials: Measuring the pharmacologic activity of ligands (affinity, efficacy, co-operativity) Determining mechanisms of action for new GPCR ligands Elements of a comprehensive and effective GPCR discovery Master advanced applications: Using new cellular assays to analyze GPCR ligand behavior Predicting activity and in vivo target coverage with real-time kinetics Discovering new ligands and GPCR behaviors for unique drug profiles   GPCR Event Highlight 11th Adhesion GPCR Workshop Join us in vibrant Mexico City from October 23-25, 2024, to connect with fellow scientists and explore the latest in adhesion GPCR biology. Logo Contest : Let your creativity shine by submitting your design for the Logo Contest before August 15, 2024 Sponsorship Opportunities :   Elevate your brand's presence at this scientific event . Contact us at Hello@DrGPCR.com   to learn more. Your participation is eagerly awaited!  Let’s dive into the   Classified GPCR News  from July 29th to August 4th, 2024 GPCR Activation and Signaling ONE-GO: Direct detection of context-dependent GPCR activity Multiplexed mapping of the interactome of GPCRs with receptor activity-modifying proteins Molecular mechanism of bitter taste receptor agonist-mediated relaxation of airway smooth muscle GPCR Binders, Drugs, and more Expanding Structure-Activity Relationships of Human Urotensin II Peptide Analogues: A Proposed Key Role of the N-Terminal Region for Novel Urotensin II Receptor Modulators GPCRs in Oncology and Immunology G protein-coupled receptor-mediated signaling of immunomodulation in tumor progression Methods & Updates in GPCR Research GPCR Signaling: A Study of the Interplay Between Structure, Energy, and Function Engineering a GPCR-based yeast biosensor for a highly sensitive melatonin detection from fermented beverages The calcium-binding photoprotein clytin II: Expression of the preferred human codon-optimized clytin II gene in Chinese hamster ovary-K1 cells and its use in the G-protein-coupled receptor assays Predicting the Hallucinogenic Potential of Molecules Using Artificial Intelligence Reviews, GPCRs, and more G protein-coupled receptor (GPCR) gene variants and human genetic disease Advances in yeast synthetic biology for human G protein-coupled receptor biology and pharmacology Industry News Muscarinic drugs breathe new life into schizophrenia pipeline GPCR Dynamics Reveal Mechanisms for Drug Discovery DMS: Linking Protein Structure To Function AbbVie Completes Acquisition of Cerevel Therapeutics Nxera Pharma attended the Drug Discovery Ecosystem Summit Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45   GPCR Events, Meetings, and Webinars September 18, 2024 | FREE Webinar - The value of GPCR cell-based assays in drug discovery October 2024 | Biologics US 2024   October 2 - 4, 2024 | 9th GPCRs in Medicinal Chemistry NEW October 17, 2024 | Unprecedented fragment-based screening using Spectral Shift for GPCRs October 23 - 25, 2024 | 11th Adhesion GPCR Workshop November 5 - 7, 2024 | 16th Annual PEGS Europe   July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs NEW Postdoc in GPCR mechanosensing   Postdoctoral Position Postdoctoral research position Senior or Lead Researcher   Senior Scientist, Cryo-Electron Microscopy   Postdoctoral Research Associate Join Dr. GPCR Ecosystem

Full Agenda Coming Soon! Are you interested in boosting your brand?

October 2022 "Systolic heart failure (HF) is a chronic clinical syndrome characterized by the reduction in cardiac function and still remains the disease with the highest mortality worldwide. Despite considerable advances in pharmacological treatment, HF represents a severe clinical and social burden. Chronic human HF is characterized by several important neurohormonal perturbations, emanating from both the autonomic nervous system and the adrenal glands. Circulating catecholamines (norepinephrine and epinephrine) and aldosterone elevations are among the salient alterations that confer significant hormonal burden on the already compromised function of the failing heart. This is why sympatholytic treatments (such as β-blockers) and renin-angiotensin system inhibitors or mineralocorticoid receptor antagonists, which block the effects of angiotensin II (AngII) and aldosterone on the failing heart, are part of the mainstay HF pharmacotherapy presently. The adrenal gland plays an important role in the modulation of cardiac neurohormonal stress because it is the source of almost all aldosterone, of all epinephrine, and of a significant amount of norepinephrine reaching the failing myocardium from the blood circulation. Synthesis and release of these hormones in the adrenals is tightly regulated by adrenal G protein-coupled receptors (GPCRs), such as adrenergic receptors and AngII receptors. In this review, we discuss important aspects of adrenal GPCR signaling and regulation, as they pertain to modulation of cardiac function in the context of chronic HF, by focusing on the 2 best studied adrenal GPCR types in that context, adrenergic receptors and AngII receptors (AT 1 Rs). Particular emphasis is given to findings from the past decade and a half that highlight the emerging roles of the GPCR-kinases and the β-arrestins in the adrenals, 2 protein families that regulate the signaling and functioning of GPCRs in all tissues, including the myocardium and the adrenal gland." Read more at the source #DrGPCR #GPCR #IndustryNews

and demonstrate its ability to promote cancer cell motility. " Authors Yu Jin Lee , Kyeong Jin Shin , Hyun-Jun Jang , Jin-Sun Ryu , Chae Young Lee , Jong Hyuk Yoon , Jeong Kon Seo , Sabin Park , Semin Lee , A Reum Je , Yang Hoon Huh , Sun-Young Kong , Taejoon Kwon , Pann-Ghill Suh , Young Chan Chae Tags GPR143 , Source Contribute to the GPCR News Coming soon Become a Contributor Classified GPCR News Call for GPCR

Authors Jong Min Hong , Jin-Woo Lee , Dong-Seung Seen , Jae-Yeon Jeong , Won-Ki Huh Tags Cancer , Chemokine , Inflammatory disease , Lysophosphatidic acid receptor 1 Source Contribute to the GPCR News Coming soon

Zhao , Vincent DiGiacomo , Mariola Ferreras-Gutierrez , Shiva Dastjerdi , Alain Ibáñez de Opakua , Jong-Chan Source Contribute to the GPCR News Coming soon Become a Contributor Classified GPCR News Call for GPCR